EXICURE, INC. Cash and Restricted Cash
EXICURE, INC. (XCUR) had Cash and Restricted Cash of $1.72 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-14
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.72M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.60M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.75M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4.44M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $1.72M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $2.60M 10-Q · filed 2026-05-29 |
| 2025-12-31 | $3.75M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $4.44M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $7.86M 10-Q · filed 2026-08-14 |
| 2025-03-31 | $10.42M 10-Q · filed 2026-05-29 |
| 2024-12-31 | $12.51M 10-Q · filed 2026-08-14 |
| 2024-09-30 | $951.00K 10-Q · filed 2025-11-07 |
| 2024-06-30 | $1.40M 10-Q · filed 2025-08-08 |
| 2024-03-31 | $1.57M 10-Q · filed 2025-06-27 |
| 2023-12-31 | $2.02M 10-K · filed 2026-03-25 |
| 2023-09-30 | $2.12M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $3.54M 10-Q · filed 2024-08-13 |
| 2023-03-31 | $11.16M 10-Q · filed 2024-06-17 |
| 2022-12-31 | $9.78M 10-K · filed 2025-03-18 |
| 2022-09-30 | $16.85M 10-Q · filed 2024-05-16 |
| 2022-06-30 | $22.40M 10-Q/A · filed 2024-06-06 |
| 2022-03-31 | $25.09M 10-Q/A · filed 2024-06-06 |
| 2021-12-31 | $43.84M 10-Q/A · filed 2024-06-06 |
| 2021-09-30 | $53.09M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $43.79M 10-Q · filed 2022-08-15 |
| 2021-03-31 | $35.50M 10-Q · filed 2022-05-16 |
| 2020-12-31 | $34.46M 10-K · filed 2023-03-27 |
| 2020-09-30 | $32.66M 10-Q · filed 2021-11-19 |
| 2020-06-30 | $18.40M 10-Q · filed 2021-08-12 |
| 2020-03-31 | $25.78M 10-Q · filed 2021-05-12 |
| 2019-12-31 | $48.46M 10-K · filed 2022-03-25 |
| 2019-09-30 | $70.39M 10-Q · filed 2020-11-12 |
| 2019-06-30 | $17.18M 10-Q · filed 2020-08-12 |
| 2019-03-31 | $22.20M 10-Q · filed 2020-05-14 |
| 2018-12-31 | $26.27M 10-K · filed 2021-03-11 |
| 2017-12-31 | $25.76M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |